Answers are grounded in this paper and cite their sources.
IgE antibodies are crucially involved in mediating, and amplifying the allergic cascade. The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Anti-IgE inhibits allergic responses by binding to serum IgE, thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of -regulating the expression of high affinity IgE on inflammatory cells, as well as the numbers eosinophils in both peripheral blood and induced sputum. Randomized clinical trials showed relevant clinical effects of omalizumab including improvements of respiratory symptoms and quality of life. Moreover, a marked reduction of asthma exacerbations, emergency room visits, and use of corticosteroids and rescue bronchodilators was also observed. Omalizumab is relatively well tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for most severe patients with persistent allergic asthma, controlled by high doses of standard treatments.
No takes yet. Share an insight, caveat, or question.
Girolamo Pelaia (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: